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Abstract
Background: The current standard treatment for resectable pancreatic cancer is surgical resection followed by
adjuvant chemotherapy. Local recurrence rates are high even after curative resection; thus, the long-term outcome
of locally advanced pancreatic cancer remains poor. Intraoperative radiotherapy (IORT) uses a low-energy x-ray source to
deliver a single fraction of high-dose radiation to the tumor bed during a surgical procedure, while effectively sparing the
surrounding normal tissues. IORT has the potential to improve the efficacy of radiation therapy for pancreatic cancer.
Methods/design: This prospective, one-armed, phase II study will investigate the role of IORT in improving local control
in patients with resectable pancreatic adenocarcinoma. The patients will receive surgery and IORT of 10 Gy prescribed at a
5-mm depth of the tumor bed, followed by adjuvant gemcitabine chemotherapy according to the current standard of
care. The aim is to enroll 42 patients.
Discussion: The primary endpoint of this trial is to evaluate the feasibility of IORT and the local recurrence rate after one
year. The secondary endpoints include the acute and late toxicities, and disease-free survival and overall survival rates.
Trial registration: The trial was prospectively registered at Clinicaltrials.gov NCT03273374 on September 6, 2017.
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Background
Pancreatic cancer is the fourth most common cause of
cancer-related mortality in the Western world [1, 2].
Although, surgical resection offers potentially curative
treatment for pancreatic adenocarcinoma, only 15–20%
of patients are candidates for curative pancreatectomy
[3]. Even after successful surgical resection, long-term
survival is rare, and the five-year survival rate of patients
with resected pancreatic adenocarcinoma is approxi-
mately 10% [4]. The predominant sites of recurrences
are both local and distant in the majority of patients
who undergo pancreatic resection, suggesting that most
patients may have occult metastatic or local/regional
disease (or both) at the time of surgery. Several pro-
spective studies have shown that combined modality
approaches using adjuvant chemotherapy or chemora-
diation in addition to surgery can improve locoregional
control and survival [5–7].
Previous trials involving external beam radiation therapy
(EBRT) have shown improved local control in combin-
ation with surgical resection [6, 8]. However, the efficacy
of EBRT in pancreatic cancer is limited by the difficulty of
delivering an adequate dose of radiation due to the limited
tolerance of critical organs, including the stomach, small
bowel, kidney, liver, and spinal cord. Furthermore, adju-
vant EBRT concurrently administered with gemcitabine is
excluded from reimbursement by the Korean National
Health Insurance. During a surgical procedure, intraoper-
ative radiation therapy (IORT) delivers a single fraction of
high-dose radiation to the tumor bed after gross total
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resection or remaining residual tumor. IORT has the
potential to improve the efficacy of radiation therapy for
pancreatic cancer by reducing radiation dose to the nor-
mal tissue and allowing the escalation of radiation dose to
the tumor bed to further improve local control [9, 10].
This is important in pancreatic cancer because local fail-
ure rates are as high as 50–80% in patients with resected
and locally advanced disease [11].
In a conventional IORT procedure, the patient has to
be transferred from the operating theater to a shielded
radiation treatment room during open laparotomy or
the entire operation must be performed in a radiation
treatment room which is inadequately equipped for sur-
gical operation [12]. Intrabeam (Carl Zeiss, Germany) is
a mobile IORT system equipped with a miniature x-ray
source of 50 kV that allows an entire IORT procedure to
be performed inside an operating theater, eliminating
the need for patient transfer during high-risk operations
such as pancreatoduodenectomy [13]. The low-energy,
50 kV peak x-ray has dose attenuation characteristics
that follow the inverse cubic law (1/r3). The steep dose
gradient generated by the Intrabeam system allows the
delivery of high-dose radiation to the tumor bed surface
while effectively limiting delivery of significant doses to
the surrounding normal tissues [14]. Furthermore, the
relative biologic effectiveness (RBE) of 50-kV x-rays from
the Intrabeam at depths clinically relevant for tumor-bed
irradiation was determined to be 1.26 to 1.42 [15], thus
increasing the likelihood of successful local control in
patients undergoing IORT using the 50-kV x-ray source.
Methods/design
Hypothesis
This trial tests the hypothesis that IORT in addition to
the current standard of care will improve local control
compared with that observed so far in patients with re-
sectable pancreatic adenocarcinoma.
Study objectives and endpoints
The primary endpoint is to evaluate the local recurrence
rate after one year. The secondary endpoints include
disease-free survival (DFS) and overall survival (OS)
rates as well as acute and late toxicities, perioperative
morbidity and mortality, and quality of life.
Study design and period
The purpose of the study is to investigate the role of
IORT in patients with primarily resectable pancreatic
cancer. The trial will be conducted as a single-center,
one-armed phase II study. The trial has been registered
at www.clinicaltrials.gov (NCT03273374). Patients will
be recruited at the Pancreatobiliary Cancer Center,
Gangnam Severance Hospital, Yonsei University College
of Medicine. The expected total duration of patient
enrollment is two years and the follow-up period is
three years.
Patient selection and enrollment criteria
Inclusion criteria
 20 years of age or older
 Histologically confirmed adenocarcinoma of the
pancreas
 Eastern Cooperative Oncology Group performance
status scores of 0–2
 Resectable disease defined as follows:
– Absence of distant metastases
– Clear fat planes around the celiac axis, hepatic
artery, and superior mesenteric artery
– Absence of direct involvement of inferior vena
cava or aorta
 Stage I–III disease per the seventh edition of the
American Joint Committee on Cancer
 Adequate bone marrow function (hemoglobin
> 10 g/dL, absolute neutrophil count > 1500/mm3,
platelets > 100,000/mm3)
 Adequate renal function (serum creatinine < 1.4mg/dL,
BUN < 20mg/dL)
 Written informed consent
Exclusion criteria
 Prior EBRT in the abdominal area
 A tumor bed which cannot be adequately covered by
the IORT field as defined by the radiation oncologist
 Neoadjuvant chemotherapy
 Unresectable disease
 Presence of distant metastases
 Pregnancy or currently nursing
Sample size calculation
The primary endpoint of the trial is the local recurrence
rate after one year. The study is designed to demonstrate
that IORT using a low-energy x-ray source delivered to
the tumor bed of the resected pancreatic cancer followed
by standard adjuvant chemotherapy can improve the
local recurrence rate after one year. The local recurrence
rate one year after resection in our institution was 36%;
the local recurrence rates after one year in comparable
patient populations treated with IORT and resection
ranged between 21 and 41.6% [16–19]. The sample size
calculation was designed on the assumption that addition
of IORT will decrease the local recurrence rate after one
year by 14% (from 36 to 22%) with a power of 80%. Using
the two-sided binomial test with a level of significance of
α = 5%, the study requires 33 patients. Assuming a
drop-out rate of 20%, a total of 42 patients will be required
for this trial.
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Pretreatment evaluation
The initial workup will consist of physical examination,
laboratory tests including tumor markers, computed
tomography (CT) or magnetic resonance imaging (MRI)
of the abdominal cavity, thoracic CT, and biopsy. Positron
emission tomography (PET) will be performed, when ne-
cessary, to detect distant metastasis. Percutaneous or endo-
scopic biliary drainage will be recommended for patients
with obstructive jaundice before or during treatment.
Treatment
All patients who fulfill the inclusion criteria and provide
written informed consent will be assigned to the treatment
regimen shown in Fig. 1. An explorative laparotomy will
be performed and the indication to continue with a resec-
tion will be based upon the absence of peritoneal or dis-
tant metastasis and the loco-regional extension of the
disease, particularly major vascular involvement. A cura-
tive resection either as pancreatoduodenectomy or distal
pancreatectomy will be performed.
The mobile 50-kV x-ray source (Intrabeam) will be
attached to the robotic arm, which maintains the stability
of the source throughout the procedure (Fig. 2). The
isotropy and output of the IORT unit are verified and the
pre-IORT calibration process required by the system is
performed prior to each treatment. The target volume of
IORT includes the tumor bed, the celiac and superior
mesenteric origins, the mesenteric root, and the portal
vein or any areas deemed risky by the surgeon and the ra-
diation oncologist. An applicator with an appropriate
diameter (3.0, 3.5, or 4.0 cm) will be selected according to
the size of the target volume, and the applicator attached
over the probe of the x-ray source. A sterile sheath will be
draped over the IORT device to prevent contamination,
and the applicator will be placed on the tumor bed by a
radiation oncologist in correspondence with the treating
surgeon. Uninvolved radiosensitive tissues will be removed
and shielded from the treatment area. After locking the
device in a treatment position and placing additional
shielding over the surgical field to protect the operators,
the target volume will be irradiated with a single dose of
10Gy, prescribed at a 5-mm depth into the tumor bed.
Eight to 12 weeks following surgery or after wound heal-
ing, the patients will receive adjuvant chemotherapy with
six cycles of gemcitabine every four weeks. Each chemo-
therapy cycle consists of three weekly gemcitabine doses
Fig. 1 Treatment schedule
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of 1000mg/m2 administered by intravenous infusion dur-
ing a 30-min period, followed by one week of rest [20].
Follow-up and assessment of efficacy
Regular follow-up visits will take place every three
months after surgery for the first two years and every six
months thereafter. Patients will be followed with phys-
ical examinations, tumor markers measurement, imaging
studies including CT or MRI of the abdominal cavity,
and PET-CT when necessary.
The local recurrence rate after one year is the primary
endpoint of the trial. It will be assessed by repeated CT,
MRI, or PET-CT during regular follow-up. In case of
suspected local recurrence, histological confirmation will be
attempted. New lesions with typical radiological signs of a
local recurrence in combination with or without increase in
the levels of tumor markers will be considered a local
recurrence. DFS and OS are the secondary endpoints of the
study. DFS will be counted from the day of surgery until
the date of the first local or distant event or death due to
any cause. Patients alive without recurrent disease at the
time of data analysis will be censored at the time of the
most recent follow-up. The OS will be determined from
the day of surgery until death due to any cause. For timed
endpoints including DFS and OS, the Kaplan-Meier sur-
vival analysis followed by multivariable Cox proportional
hazards model for adjusting for baseline variables will be
used. P-values < 0.05 will be considered significant. Patients
alive or lost to follow-up will be censored at the date of the
last follow-up visit. Toxicity will be assessed according to
Common Terminology Criteria for Adverse Events Version
3.0. Any toxicity occurring within three months after
surgery will be considered acute toxicity. Late toxicity will
be assessed during the regular follow-up visits.
Safe evaluation and reporting of adverse effects
Adverse and serious adverse events must be reported in
order to protect participants. Study participation will be
terminated, if the patient suffers from a grade 4 toxicity
related to treatment, if a different treatment is required
that is not approved in this trial, or if the patient with-
draws consent for further participation. Serious adverse
events will be reported within seven days of detection by
the investigators.
Discussion
This trial investigates whether the addition of IORT
using a low-energy x-ray source to the standard treat-
ment, consisting of surgical resection (pancreatoduode-
nectomy or distal pancreatectomy) followed by adjuvant
chemotherapy, improves the local recurrence rate after
one year. The treatment outcomes of pancreatic cancer
remain poor and local failure rates are as high as 50–
80% in patients with resected and locally advanced
disease [11]. The physical characteristics and relative
biological effectiveness of 50 kV x-ray allow high-dose
irradiation of the tumor bed while effectively sparing
the surrounding normal tissues [14, 15]. The mobile
Intrabeam IORT system also allows a single-fraction
treatment during surgery without having to transfer
the patient out of the operating theater.
The treatment schedule in this study consists of pan-
creatoduodenectomy or distal pancreatectomy and IORT
followed by adjuvant chemotherapy of full-dose gemcita-
bine (1000 mg/m2). Unlike adjuvant EBRT, IORT does
not require delayed administration or dose reduction of
adjuvant gemcitabine due to the increased risk of radi-
ation toxicity with concurrent administration. Further-
more, IORT allows an additional treatment option of
Fig. 2 The Intrabeam IORT procedure
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adjuvant EBRT for high-risk patients such as those with
narrow R0 or R1 resection in the final pathology report.
IORT with a mobile low-energy x-ray source has po-
tential to improve local control; this phase II trial will
evaluate the role of IORT in patients with resectable
pancreatic cancer.
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